Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Adial PharmaceuticalsADIL +2.59%30 EV-to-FCF is 1.18 as of Aug. 26, 2026. GuruFocus rates ADIL with a GF Score™ of 30/100. The stock has 1 warning sign investors should review. Among 320 Biotechnology companies, Adial Pharmaceuticals ranks better than 77.81% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Adial Pharmaceuticals's Enterprise Value is $-13.11 Mil.
Adial Pharmaceuticals's Free Cash Flow for the trailing twelve months (TTM) ended in Jun. 2026 was $-11.13 Mil. Therefore, Adial Pharmaceuticals's EV-to-FCF for today is 1.18.
The historical rank and industry rank for Adial Pharmaceuticals's EV-to-FCF or its related term are showing as below:
ADIL'
s EV-to-FCF Range Over the Past 10 Years
Min: 0 Med: 0 Max: 1.25
Current: 1.18
During the past 11 years, the highest EV-to-FCF of Adial Pharmaceuticals was 1.25. The lowest was 0.00. And the median was 0.00.
ADIL's EV-to-FCF is ranked better than 77.81% of 320
companies
in the Biotechnology industry
Industry Median: 17.77
vs ADIL: 1.18
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Adial Pharmaceuticals's PE Ratio (TTM) for today is calculated as:
Adial Pharmaceuticals's share price for today is $5.94.
Adial Pharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-16.527.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Adial Pharmaceuticals's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Adial Pharmaceuticals EV-to-FCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Adial Pharmaceuticals's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Adial Pharmaceuticals's EV-to-FCF falls into.
Adial Pharmaceuticals's current Enterprise Value is $-13.11 Mil.
Adial Pharmaceuticals's Free Cash Flow for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-11.13 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Adial Pharmaceuticals (ADIL) has a EV-to-FCF of 1.18 as of Aug. 26, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Adial Pharmaceuticals and its competitors. According to the industry distribution chart, Adial Pharmaceuticals ranks #71 out of 320 companies in the Biotechnology industry, placing it in the top 22.2%.
Is Adial Pharmaceuticals' EV-to-FCF too high?
Adial Pharmaceuticals' current EV-to-FCF is 1.18. The Biotechnology industry median EV-to-FCF is 17.77. Adial Pharmaceuticals' value of 1.18 is 93.4% below this industry median. Based on the distribution chart, Adial Pharmaceuticals ranks #71 out of 320 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Adial Pharmaceuticals has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does Adial Pharmaceuticals' EV-to-FCF compare to PULM and KAPA?
According to the Biotechnology industry distribution chart, Adial Pharmaceuticals ranks #71 out of 320 companies for EV-to-FCF. This places Adial Pharmaceuticals in the top 22% of its industry — outperforming the majority of peers. The industry median EV-to-FCF is 17.77. Adial Pharmaceuticals' value of 1.18 is 93.4% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Biotechnology company?
The median EV-to-FCF among Biotechnology companies is 17.77, based on 320 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Adial Pharmaceuticals's current EV-to-FCF of 1.18 is 93.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Adial Pharmaceuticals and its competitors. For the Biotechnology industry, the median EV-to-FCF is 17.77 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Adial Pharmaceuticals's current EV-to-FCF is 1.18. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Adial Pharmaceuticals stock overvalued right now?
Adial Pharmaceuticals (ADIL) has a current EV-to-FCF of 1.18. The current EV-to-FCF is 1.18 and 93.4% below the Biotechnology industry median of 17.77. Adial Pharmaceuticals' overall GF Score™ is 30/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Adial Pharmaceuticals (ADIL), the current EV-to-FCF is 1.18 as of Aug. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Adial Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its investigational new drug candidate, AD04, is being developed as a therapeutic agent for the treatment of alcohol use disorder. The company operates as one operating segment with a focus on drug development for addiction and related disorders.
30GF Score
Get the complete analysis for ADIL
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ADIL has been successfully added to your 
